# Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

> **NCT02256774** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 51 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BILR 355 BS
- **DRUG:** Combivir®
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT02256774
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2005-05
- **Final completion:** —
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256774, "Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02256774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*